Australian Clinical Labs Limited Ratios | P/E, ROE & Valuation

On this page, ACL's current P/E is 15.9, compared with a multi-year average around 14.4. A higher P/E versus its own history can indicate the market is pricing in stronger earnings growth or better durability. To judge whether the premium is justified, cross-check profitability (ROE/ROIC), liquidity (current ratio), and leverage (debt-to-equity) so you can separate quality strength from expectations alone.

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $440.18M. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

There isn't one universal "good" P/E - P/E should be judged against the business model and expected growth for its sector. A practical approach is: (1) compare the P/E on this page to Australian Clinical Labs Limited's own historical range (shown across the table's rows), and (2) benchmark against peer companies using the Screener's P/E filters and the Peers Comparison/Compare tools. If profitability (ROE/ROIC) and cash-flow strength are improving, a higher P/E can be more defensible; if returns are slipping, even a lower P/E may be a value trap.

The fastest way to compare Australian Clinical Labs Limited with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Australian Clinical Labs Limited outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

To assess whether Australian Clinical Labs Limited is financially strong, review both profitability and balance-sheet risk together. Current ratio is about 0.59, which is below 1.0 and can suggest tighter short-term liquidity. Interest coverage is about 9.08, implying a stronger ability to cover interest expenses. Debt-to-equity is about 3.01, suggesting higher leverage than a low-debt profile. Then confirm the same story is supported by ROE/ROIC (quality of earnings) and by cash-flow backed metrics in the table.

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Australian Clinical Labs Limited is sustaining strong returns (for example ROE at 16.35% and ROIC at 21.96%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.